GSK, Novartis Offer EU Antitrust Fixes On $23B Deals
Novartis AG and GlaxoSmithKline PLC on Wednesday offered Europe's competition watchdog unspecified fixes on deals worth nearly $23 billion combined, including Novartis' $16 billion acquisition of rival GSK's cancer drugs, giving...To view the full article, register now.
Already a subscriber? Click here to view full article